1 Participate in many phase II and III global lung cancer treatment trial, including target therapy and immunotherapy in advanced stage and early stage of NSCLC; such as the development of Afatinib, Ramicirumab plus erlotinib in EGFR mutant NSCLC,, listed as the co-author of publications in Lancet Oncology, Clinical Cancer Research, etc. 2 Involved in International conference committee of IASLC Asia and APSR and as an invited speaker in WCLC. 3 As a PI of phase I trials of BOS172738 (an novel RET inhibitor) in RET fusion NSCLC; phase I/II trial BA3021 in combination of nivoluma; 4 Initiate an investigator initiated trial about combination of pemetrexed, platinum, atezolizumab and bevacizumab in EGFR TKI failed T790M (-) EGFR mutant lung cancer. 5 Has been audited by USA FDA for registration trial.